In Brief
Refine Search
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Pharmaceutical
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Pharmaceutical
Plenty of companies in the pharmaceutical industry talk the talk when it comes to focusing on patients. 6 August 2024
Biotechnology
US clinical-stage biotech Equillium saw its shares rise 8% to $0.68 as it revealed progress with its first-in-class anti-CD6 monoclonal antibody. 6 August 2024
Pharmaceutical
Life sciences venture capital company Apple Tree Partners (ATP) has unveiled Red Queen Therapeutics, a biotech developing antivirals for the general population and especially for immunocompromised patients at increased risk of serious illness or death from common and emerging viral pathogens. 6 August 2024
Biotechnology
Daiichi Sankyo (and US pharma giant Merck & Co have expanded their existing global co-development and co-commercialization agreement to include Merck’s MK-6070. 6 August 2024
Biotechnology
The US subsidiary of Swiss family-owned protein specialist Octapharma today revealed that the US Food and Drug Administration (FDA) has expanded the approval of fibryga, fibrinogen (human) lyophilized powder for reconstitution, for fibrinogen replacement in bleeding patients with acquired fibrinogen deficiency (AFD). 6 August 2024
Biotechnology
Shares of Swiss antibody drug conjugates (ADCs) develop ADC Therapeutics were down more than 11% at $2.55 as it reported financial results for 2nd-qtr 2024 and provided operational updates. 6 August 2024
Pharmaceutical
Germany’s Bayer has reported group revenue of 11.1 billion euros ($12.2 billion) in the second quarter of 2024, ahead of the 10.9 billion euros average of analysts’ estimates and up by 1% on the same period a year ago. 6 August 2024
Pharmaceutical
Shanghai-based Antengene (SEHK: 6996) has announced that the Malaysian medicines regulator has approved Xpovio (selinexor) for the treatment of multiple myeloma. 6 August 2024
Biotechnology
Actinium Pharmaceuticals’ shares closed down 60% yesterday and fell a further 10% to $2.23 in after-hours trading, when the company announced a regulatory setback for its Iead candidate. 6 August 2024
Biotechnology
US clinical-stage MBX Biosciences yesterday announced a $63.5 million Series C financing led by Deep Track Capital, 6 August 2024
Biotechnology
California’s BioMarin Pharmaceutical (Nasdaq: BMRN) has announced a strategic pivot for its Roctavian (valoctocogene roxaparvovec-rvox) business, focusing on the USA, Germany, and Italy. 6 August 2024
Biotechnology
In Singapore, a division of Kyowa Kirin (TSE:4151), has announced plans to sell the firm’s Chinese business while reducing focus on small molecules, as part of a regional overhaul. 6 August 2024
Biotechnology
Biotech incubators Two River and Third Rock Ventures have launched TRC 2004, a new company focusing on bispecific T-cell engagers (BiTE), according to a filing with the Hong Kong Stock Exchange. 6 August 2024
Biosimilars
The Biosimilars Council—part of the USA’s Association for Accessible Medicine (AAM) representing companies developing off-patent medicines—has provided an update on its activities on the regulatory, legislative and educational fronts. 5 August 2024
Generics
Imports of bulk drugs from China have jumped, potentially undermining India's efforts to boost domestic pharmaceutical manufacturing through its Production Linked Incentive (PLI) scheme. 5 August 2024
Biotechnology
Agenus has revealed via a Securities and Exchange Commission (SEC) filing that US pharma major Bristol Myers Squibb (NYSE: BMS) was pulling out of a licensing deal. 5 August 2024
Biotechnology
US immune-oncology firm iTeos Therapeutics today announced the appointment of David Feltquate as chief medical officer (CMO). 5 August 2024
Biotechnology
German biotech BioNTech today reported financial results for the three ended June 30, 2024, which failed to impress.. 5 August 2024
Biotechnology
Californian firm Anivive Lifesciences is broadening its scope from animal health to human vaccines with a significant new funding grant. 5 August 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze